Katherine R. Tuttle

1991–2026 年に発表

別表記
Katherine R Tuttle · KATHERINE R. TUTTLE
227
論文数
39,259
被引用数
87
h 指数
205
i10 指数

被引用数

Katherine R. Tuttle の年別被引用数1900 年: 被引用 1 件1992 年: 被引用 6 件1993 年: 被引用 1 件1994 年: 被引用 3 件1996 年: 被引用 4 件1997 年: 被引用 1 件1998 年: 被引用 4 件1999 年: 被引用 5 件2000 年: 被引用 6 件2001 年: 被引用 11 件2002 年: 被引用 25 件2003 年: 被引用 42 件2004 年: 被引用 48 件2005 年: 被引用 59 件2006 年: 被引用 93 件2007 年: 被引用 80 件2008 年: 被引用 101 件2009 年: 被引用 61 件2010 年: 被引用 74 件2011 年: 被引用 91 件2012 年: 被引用 89 件2013 年: 被引用 87 件2014 年: 被引用 104 件2015 年: 被引用 92 件2016 年: 被引用 109 件2017 年: 被引用 138 件2018 年: 被引用 171 件2019 年: 被引用 666 件2020 年: 被引用 945 件2021 年: 被引用 1,135 件2022 年: 被引用 1,210 件2023 年: 被引用 1,214 件2024 年: 被引用 2,999 件2025 年: 被引用 2,592 件2026 年: 被引用 144 件1901〜1991 年は被引用が無いため表示していません1995 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,335 件、この内訳の 21%中国: 引用元論文 2,184 件、この内訳の 13.7%イギリス: 引用元論文 1,001 件、この内訳の 6.3%イタリア: 引用元論文 670 件、この内訳の 4.2%ドイツ: 引用元論文 651 件、この内訳の 4.1%オーストラリア: 引用元論文 631 件、この内訳の 4%カナダ: 引用元論文 611 件、この内訳の 3.8%日本: 引用元論文 519 件、この内訳の 3.3%オランダ: 引用元論文 434 件、この内訳の 2.7%スペイン: 引用元論文 425 件、この内訳の 2.7%フランス: 引用元論文 330 件、この内訳の 2.1%デンマーク: 引用元論文 295 件、この内訳の 1.8%
0%21%その他 30.3%

分野

  • Medicine80.3%
  • Biochemistry, Genetics and Molecular Biology11.5%
  • Health Professions1.3%
  • Immunology and Microbiology1.2%
  • Computer Science1%
  • Nursing0.8%
  • その他3.9%

トピック

  • Chronic Kidney Disease and Diabetes9.9%
  • Diabetes Treatment and Management8.2%
  • Dialysis and Renal Disease Management3.8%
  • Gout, Hyperuricemia, Uric Acid2.5%
  • Renal Diseases and Glomerulopathies2.4%
  • Blood Pressure and Hypertension Studies2.2%
  • その他71%

共著者

全論文

検索で開く
  1. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

    著者: , , , , , , , , , , - New England Journal of Medicine 2024 被引用: 1,520

  2. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2023 被引用: 1,653

  3. Diabetic Kidney Disease

    著者: , , - Clinical Journal of the American Society of Nephrology 2017 被引用: 2,776

  4. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease

    著者: , , , , , , , , , , , , , , , , - Kidney International 2022 被引用: 1,214

  5. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2023 被引用: 1,088

  6. Development and Validation of the American Heart Association’s PREVENT Equations

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2023 被引用: 929

  7. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association

    著者: , , , , , , , , , , , , , , - Circulation 2023 被引用: 659

  8. Molecular mechanisms and therapeutic targets for diabetic kidney disease

    著者: , , , , , , - Kidney International 2022 被引用: 624

  9. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease

    著者: , , , , , , , , , , , , , , , , - Kidney International 2020 被引用: 1,403

  10. Kidney Disease and Increased Mortality Risk in Type 2 Diabetes

    著者: , , , , , , - Journal of the American Society of Nephrology 2013 被引用: 1,268

  11. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

    著者: , , , , , , , , , , , , , - Nephrology Dialysis Transplantation 2023 被引用: 237

  12. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial

    著者: , , , , , , , , - The Lancet Diabetes & Endocrinology 2022 被引用: 279

  13. Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014

    著者: , , , , , , - JAMA 2016 被引用: 1,015

  14. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

    著者: , , , , , , - The Lancet Diabetes & Endocrinology 2018 被引用: 635

  15. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Endocrine Practice 2022 被引用: 469

  16. Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kazumasa Yamagishi, Isao Muraki, Yūji Shimizu, Hiroyasu Iso, Masafumi Fukagawa, Shoichi Maruyama, Takayuki Hamano, Naohiko Fujii, Takahiro Imaizumi, Natália Alencar de Pinho, Marie Metzger, Bénédicte Stengel, Aghilès Hamroun, Ziad Massy, Tazeen H. Jafar, Imtiaz Jehan, Juanita Hatcher, Nish Chaturvedi, Neil R Poulter, David C. Wheeler, Martin Landray, Amanda Anderson, Jing Chen, James Lash, Jon Taliercio, Peter Yang, Katherine R. Tuttle, Radica Alicic, Susanne B. Nicholas, Jenny I. Shen, Ben Schöttker, Hannah Stocker, Dietrich Rothenbacher, Hermann Brenner, Daniel Levy, Shih‐Jen Hwang, Markus P. Schneider, Anna Köttgen, Heike Meiselbach, Kai‐Uwe Eckardt, Alex R. Chang, Jamie A. Green, H. Lester Kirchner, Gurmukteshwar Singh, Simon Sawhney, Corri Black, Katie Wilde, Angharad Marks, Samira Bell, Moneeza K. Siddiqui, Colin Palmer, Ewan R. Pearson, Mariko Miyazaki, Masaaki Nakayama, Tae Yamamoto, Gen Yamada, Sadayoshi Ito, Massimo Círillo, Angela Yee‐Moon Wang, Henry H. L. Wu, Hoi Ching Cheung, Victoria Ngai, Tang Ka Tak, Amit X. Garg, Eric McArthur, Ann Young, Vivekanand Jha, Ashok Kumar Yadav, Vivek Kumar, April P. Carson ほか 217 名 - JAMA 2023 被引用: 315

  17. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dick de Zeeuw, Peter Rossing, Cheuk‐Chun Szeto, Diego Echeverri, Edouard Martin, Ming Li Yee, William Wah, Ray Wang, Bobby Chacko, Shriram Swaminathan, Richard J. MacIsaac, Hikaru Hashimura, Glenn M. Ward, Katrien De Vusser, Kathleen Claes, Dirk Kuypers, Björn Meijers, Amaryllis H. Van Craenenbroeck, Robert Hilbrands, Corinne Debroye, Karl Martin Wissing, Michel Jadoul, Nathalie Demoulin, Serge Treille de Grandsaigne, Ishak Beklevic, Diane Marcoux, F Liénart, Claude Daper, V de Brouckère, Mercédès Heureux, João Soares Felício, Karem Miléo Felício, Daniella Leite, Franciane Trindade Cunha de Melo, Natércia Neves Marques de Queiroz, Ana Carolina Souza, Jocyelle Vieira, Roberto Jorge da Silva Franco, Adriana Aparecida Mendes, Giovana Picolli, Luís Henrique Santos Canani, Carla Sartori, Adriana Valenti, Freddy G. Eliaschewitz, Renata Luísa Bona, Denise Reis Franco, Denise Ludovico Costa de Castro, Vanessa Magalhaes, Marcelo G. de Oliveira, Célia Regina Sampaio, Guilherme Visconti, Bruno Halpern, Camila Nihei, Bruna V. Pessoa, Carlos Eduardo Seraphim, Daniel Barbedo Vasconcelos Santos, Cláudia Brito, J. B. Douverny, Marina Colella, Cristina Gazeta, Monique Vercia, Renato Watanabe, Theodora Temelkova, Dimo Kjurkchiev, Silviya Statkova, Iliya Popov, Radosveta Radeva, Lachezar Arabadzhiev, Mariya Binova, Aleksandar Bosilkov ほか 463 名 - The Lancet 2023 被引用: 187

  18. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

    著者: , , , , , , , , , , , , , , , - Nature Medicine 2024 被引用: 197

  19. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence

    著者: , , , , , , , , , , , , , , , , , , , , , - Kidney International 2022 被引用: 268

  20. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gloria Ashuntantang, Shakti Basnet, Aminu K. Bello, Worawon Chailimpamontree, Ricardo Correa‐Rotter, Jonathan C. Craig, Walter Douthat, Harold I. Feldman, Mohammad Reza Ganji, Guillermo García-García, Mohammed Benghanem Gharbi, David C.H. Harris, Vivekanand Jha, David W. Johnson, Rümeyza Kazancıoğlu, Robyn G. Langham, Zhi-Hong Liu, Ziad A. Massy, Masaomi Nangaku, Robert G. Nelson, Dónal O’Donoghue, Ikechi G. Okpechi, Roberto Pecoits‐Filho, Neil R. Powe, Giuseppe Remuzzi, Charlotte Roberts, Jérôme Rossert, Laura Solá, Bénédicte Stengel, Ernest K. Sumaili M, Yusuke Suzuki, Tetsuhiro Tanaka, Sajja Tatiyanupanwong, Bernadette Thomas, Katrin Uhlig, Robert G. Walker, S. L. White, Andrzej Więcek, Chih-Wei Yang - The Lancet 2017 被引用: 923

  21. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

    著者: , , , , , , , , , , , , , , , , , - Nature Medicine 2024 被引用: 154

  22. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials

    著者: , , , , , , , , , , , , , , - The Lancet Diabetes & Endocrinology 2024 被引用: 268

  23. Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update

    著者: , , , , , , , , , , , , , , , , , , , , , - Annals of Internal Medicine 2023 被引用: 236

  24. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection

    著者: , , , - American Journal of Preventive Cardiology 2023 被引用: 112